CEA

Introduction to CEA

Carcinoembryonic antigen (CEA) is a set of glycoproteins involved in cell adhesion. It is typically used as a tumor marker in clinical settings, particularly for cancers of the colon, rectum, and other organs. Elevated CEA levels can indicate the presence of cancer, making it a valuable tool for diagnosis and monitoring treatment efficacy.

What is CEA 125?

CEA 125, commonly referred to as CA-125, is another type of tumor marker used primarily to monitor ovarian cancer. Like CEA, CA-125 is a glycoprotein, but it is specifically associated with epithelial ovarian cancer. Elevated levels of CA-125 can indicate the presence of ovarian cancer, although it can also be elevated in non-malignant conditions, such as endometriosis or pelvic inflammatory disease.

Key Differences Between CEA and CEA 125

While both CEA and CEA 125 are tumor markers, they serve different purposes and are associated with different types of cancer. CEA is primarily used for cancers of the colon and rectum, while CA-125 is used for ovarian cancer. Additionally, the conditions that elevate these markers differ; for instance, CEA levels may rise in smokers or those with inflammatory bowel disease, whereas CA-125 can be elevated due to non-malignant gynecological conditions.

Conclusion

Understanding the differences between CEA and CA-125 is crucial for accurate diagnosis and treatment. While both serve as important biomarkers in oncology, their specific applications vary significantly. Being informed about these distinctions can aid healthcare professionals in making more precise diagnostic and therapeutic decisions.